Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

University of Colorado Hospital

Principal Investigator
Photograph of Karl Lewis,  MD

Karl Lewis, MD

Study ID

Protocol Number: 22-0094

More information available at ClinicalTrials.gov: NCT04140526

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers